

# ESC Congress 2020

The Digital Experience



29 August  
to 1 September



## Live Sessions Programme

Saturday, 29 August CEST	Sunday, 30 August CEST	Monday, 31 August CEST	Tuesday, 1 September CEST
14:00 - 14:30 Inaugural Session	14:00 - 14:30 Hot Line 4: ATPCI - Trimetazidine in Angina Patients with Recent Successful Percutaneous Coronary Intervention: a Randomized, Double-Blind, Placebo-Controlled Trial	14:00 - 14:30 Hot Line 7: LoDoCo2 Low-Dose Colchicine in Coronary Disease	14:00 - 14:30 Hot Line 10: BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19
14:30 - 15:00 Hot Line 1: EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes	14:30 - 15:00 Hot Line 5: POPULAR TAVI - Aspirin With or Without Clopidogrel after Transcatheter Aortic Valve Implantation	14:30 - 15:00 Hot Line 8: HOME-PE - Hospitalisation or Outpatient Management of PE Patients - HESTIA vs. Simplified PESI	14:30 - 15:00 Hot Line 11: IMPACT-Afib Implementation of Stroke Prevention in Atrial Fibrillation
15:00 - 15:30 Industry Live – MSD: Expanding Understanding For Patients With Diabetes and Cardiovascular Disease – Results From The VERTIS CV Trial	15:00 - 15:30 Industry Live – AstraZeneca: Learning from DAPA-HF one year on: Expert on the spot	15:00 - 15:30 Industry Live – Pfizer: Faces and Cases: Improving the Management of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	15:00 - 15:30 Industry Live – Amgen: PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients
15:30 - 16:00 Hot Line 2: EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy	15:30 - 16:30 2020 ESC Guidelines on Non-ST-Segment Elevation Acute Coronary Syndromes	15:30 - 16:30 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease	15:30 - 16:30 2020 ESC Guidelines on Adult Congenital Heart Disease
16:00 - 17:00 2020 ESC Guidelines on Atrial Fibrillation	16:30 - 17:00 Hot Line 6: PARALLAX: Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF	16:30 - 17:00 Hot Line 9: BPLTTC - Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure	16:30 - 17:00 Hot Line 12: REALITY - A Trial of Transfusion Strategies for Myocardial Infarction and Anemia
17:00 - 17:30 Hot Line 3: EAST – AFNET 4: Effects of Early Rhythm Control Therapy in Patients with Atrial Fibrillation	17:00 - 17:30 ESC Gold Medals	17:00 - 17:30 Awards Ceremony – Inspirational Lecture	17:00 - 17:30 Special session
17:30 - 18:15 Industry Live - Novartis Pharma AG: Making essential treatment choices in heart failure	17:30 - 18:15 Industry Live - Boehringer Ingelheim: Advances in Heart Failure - Is it Time to Redefine Patient Selection for SGLT2 Inhibitors?	17:30 - 18:15 Industry Live - Novartis Pharma AG: Lower for Longer: Reducing Cumulative Exposure to Elevated LDL-C to Prevent Cardiovascular Disease	17:30 - 18:15 Industry Live – Amgen: LDL Management in ACS: Lower is better but is Earlier better?
18:15 - 18:30 Saturday Daily Wrap Up	18:15 - 18:30 Sunday Daily Wrap Up	18:15 - 18:30 Monday Daily Wrap Up	18:15 - 18:30 Tuesday Daily Wrap Up

(as of 24 July 2020)